Expanding the genotype and phenotype spectrum of SYT1-associated neurodevelopmental disorder

Synaptotagmin-1 (SYT1) is a critical mediator of neurotransmitter release in the central nervous system. Previously reported missense SYT1 variants in the C2B domain are associated with severe intellectual disability, movement disorders, behavioural disturbance and EEG abnormalities. Here, we expand the genotypes and phenotypes and identify discriminating features of this disorder. We describe 22 individuals with 15 de novo missense SYT1 variants. Evidence for pathogenicity is discussed, including ACMG criteria, known structure-function relationships, and molecular dynamics simulations. Quantitative behavioural data for 14 cases are compared to other monogenic neurodevelopmental disorders. Four variants lie in the C2A domain with the remainder in the C2B. We classify 6 variants as pathogenic, 4 as likely pathogenic, and 5 as variants of uncertain significance. Prevalent clinical phenotypes include delayed developmental milestones, ophthalmic problems, movement disorders and sleep disturbance. Discriminating behavioural characteristics were severity of motor and communication impairment, presence of motor stereotypies and mood instability. SYT1 variants associated with neurodevelopmental disorder extend beyond previously reported regions, and the phenotypic spectrum encompasses a broader range of severity than initially reported. This work guides diagnosis and molecular understanding of this rare neurodevelopmental disorder, and highlights a key role for SYT1 function in emotional regulation, motor control and emergent cognitive function.

[1]  Christopher G Chute,et al.  The Human Phenotype Ontology in 2021 , 2020, Nucleic Acids Res..

[2]  A. Poliakov,et al.  Identification of a Novel de Novo Variant in the SYT2 Gene Causing a Rare Type of Distal Hereditary Motor Neuropathy , 2020, Genes.

[3]  Patrick J. Short,et al.  Evidence for 28 genetic disorders discovered by combining healthcare and research data , 2020, Nature.

[4]  S. Gordon,et al.  Disorders of synaptic vesicle fusion machinery , 2020, Journal of neurochemistry.

[5]  K. Baker,et al.  The neurodevelopmental spectrum of synaptic vesicle cycling disorders , 2020, Journal of neurochemistry.

[6]  M. Verhage,et al.  SNAREopathies: Diversity in Mechanisms and Symptoms , 2020, Neuron.

[7]  H. Mefford,et al.  De novo variants in SNAP25 cause an early-onset developmental and epileptic encephalopathy , 2020, Genetics in Medicine.

[8]  M. Cousin,et al.  Presynaptic dysfunction in neurodevelopmental disorders: Insights from the synaptic vesicle life cycle , 2020, Journal of neurochemistry.

[9]  R B Sutton,et al.  Molecular Basis for Synaptotagmin-1-Associated Neurodevelopmental Disorder , 2020, Neuron.

[10]  M. R. Bowers,et al.  Synaptotagmin: Mechanisms of an electrostatic switch , 2020, Neuroscience Letters.

[11]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[12]  Joseph S. Briguglio,et al.  Synaptotagmin 1 clamps synaptic vesicle fusion in mammalian neurons independent of complexin , 2019, Nature Communications.

[13]  J. Littleton,et al.  Identification of a new SYT2 variant validates an unusual distal motor neuropathy phenotype , 2018, Neurology: Genetics.

[14]  Ingo Borggraefe,et al.  SYT1-associated neurodevelopmental disorder: a case series , 2018, Brain : a journal of neurology.

[15]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[16]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[17]  R. Gibbs,et al.  SYT1-associated neurodevelopmental disorder: a case series , 2018, Brain : a journal of neurology.

[18]  E. Kavalali,et al.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets , 2017, Pharmacological Reviews.

[19]  S. Rüdiger,et al.  A script to highlight hydrophobicity and charge on protein surfaces , 2015, Front. Mol. Biosci..

[20]  D. Valle,et al.  GeneMatcher: A Matching Tool for Connecting Investigators with an Interest in the Same Gene , 2015, Human mutation.

[21]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[22]  Nicholas K. Sauter,et al.  Architecture of the Synaptotagmin-SNARE Machinery for Neuronal Exocytosis , 2015, Nature.

[23]  Torsten Baldeweg,et al.  Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling. , 2015, The Journal of clinical investigation.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  E. Mercuri,et al.  Novel de novo heterozygous loss-of-function variants in MED13L and further delineation of the MED13L haploinsufficiency syndrome , 2015, European Journal of Human Genetics.

[26]  J. Littleton,et al.  Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. , 2014, American journal of human genetics.

[27]  Teryn P. Bruni,et al.  Test Review: Social Responsiveness Scale–Second Edition (SRS-2) , 2014 .

[28]  S. Hell,et al.  Phosphatidylinositol 4,5-bisphosphate clusters act as molecular beacons for vesicle recruitment , 2013, Nature Structural &Molecular Biology.

[29]  S. Sparrow,et al.  Vineland Adaptive Behavior Scales, Second Edition , 2012 .

[30]  J. Littleton,et al.  Differential regulation of synchronous versus asynchronous neurotransmitter release by the C2 domains of synaptotagmin 1 , 2010, Proceedings of the National Academy of Sciences.

[31]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[32]  C. Drew Vineland Adaptive Behavior Scales , 2010 .

[33]  T. Südhof,et al.  Differential but convergent functions of Ca2+ binding to synaptotagmin-1 C2 domains mediate neurotransmitter release , 2009, Proceedings of the National Academy of Sciences.

[34]  Zhiping P. Pang,et al.  Synaptotagmin-1 functions as the Ca2+-sensor for spontaneous release , 2009, Nature Neuroscience.

[35]  Manuel Corpas,et al.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.

[36]  E. Chapman,et al.  Ca2+-Dependent, Phospholipid-Binding Residues of Synaptotagmin Are Critical for Excitation–Secretion Coupling In Vivo , 2008, The Journal of Neuroscience.

[37]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[38]  Kurt W. Marek,et al.  Synaptotagmin I is necessary for compensatory synaptic vesicle endocytosis in vivo , 2003, Nature.

[39]  M. Jackson,et al.  Mutations in the Effector Binding Loops in the C2A and C2B Domains of Synaptotagmin I Disrupt Exocytosis in a Nonadditive Manner* , 2003, Journal of Biological Chemistry.

[40]  C. Stevens,et al.  The Synaptotagmin C2A Domain Is Part of the Calcium Sensor Controlling Fast Synaptic Transmission , 2003, Neuron.

[41]  J. Rizo Faculty Opinions recommendation of The C(2)B Ca(2+)-binding motif of synaptotagmin is required for synaptic transmission in vivo. , 2003 .

[42]  I. Robinson,et al.  The C2B Ca2+-binding motif of synaptotagmin is required for synaptic transmission in vivo , 2002, Nature.

[43]  T. Südhof,et al.  Three-Dimensional Structure of the Synaptotagmin 1 C2B-Domain Synaptotagmin 1 as a Phospholipid Binding Machine , 2001, Neuron.

[44]  T. Südhof,et al.  Synaptotagmin I functions as a calcium regulator of release probability , 2001, Nature.

[45]  T. Südhof,et al.  Solution structures of the Ca2+-free and Ca2+-bound C2A domain of synaptotagmin I: does Ca2+ induce a conformational change? , 1998, Biochemistry.

[46]  T. Südhof,et al.  Ca2+ binding to synaptotagmin: how many Ca2+ ions bind to the tip of a C2‐domain? , 1998, The EMBO journal.

[47]  T. Südhof,et al.  Differential distributions of novel synaptotagmins: Comparison to synapsins , 1995, Neuropharmacology.

[48]  S. Seino,et al.  Cellular localization of synaptotagmin I, II, and III mRNAs in the central nervous system and pituitary and adrenal glands of the rat , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  S. Sprang,et al.  Structure of the first C2 domain of synaptotagmin I: A novel Ca2+/phospholipid-binding fold , 1995, Cell.

[50]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[51]  T. Südhof,et al.  Domain structure of synaptotagmin (p65) , 1991, The Journal of biological chemistry.

[52]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[53]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[54]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .